Pfizer (NYSE:PFE) Q1 2026 earnings beat Wall Street estimates with USD 14.45 billion in revenue and USD 0.75 adjusted EPS, as newer oncology and cardiovascular products drive non-Covid growth.

Key Highlights

  • Pfizer reported Q1 2026 adjusted EPS of USD 0.75, beating the USD 0.72 consensus estimate.
  • Revenue reached USD 14.45 billion, up 5% year over year, exceeding the USD 13.79 billion forecast.
  • Launched and acquired products grew 22% operationally, led by Padcev, Eliquis, and Nurtec.
  • Covid product revenues continued their structural decline, with Paxlovid down 63% and Comirnaty down 59% operationally.
  • Full-year 2026 guidance reaffirmed: revenue of USD 59.5 to USD 62.5 billion and adjusted EPS of USD 2.80 to USD 3.00.

A Beat Built on Non-Covid Foundations

Pfizer (NYSE:PFE) entered 2026 under pressure to demonstrate that its commercial engine could sustain itself without the windfall Covid revenues that defined 2021 and 2022. The first quarter offered a measured but credible answer. Revenue of USD 14.45 billion came in ahead of analyst expectations and represented a 5% reported increase over the prior-year period. Operationally, stripping out foreign exchange effects, growth was a more modest 2%. Yet excluding Comirnaty and Paxlovid entirely, the underlying business expanded 7% operationally, a figure that carries more analytical weight for investors evaluating the durability of Pfizer's post-Covid portfolio.

Adjusted earnings per share of USD 0.75 cleared the USD 0.72 consensus, though reported net income fell to USD 2.69 billion from USD 2.97 billion a year earlier, reflecting higher cost of sales and increased R&D expenditure. Adjusted EPS itself declined from USD 0.92 in Q1 2025, a reminder that absolute profitability remains under structural pressure even as revenue surprises to the upside.

The Products Driving Growth

The operational story of the quarter belongs to a cluster of oncology, cardiovascular, and neurology assets. Eliquis, Pfizer's blood thinner co-commercialised with Bristol-Myers Squibb, generated USD 2.17 billion in quarterly sales, up 13% year over year and ahead of the USD 1.96 billion analyst estimate. The drug continues to benefit from global demand, though generic erosion in select international markets remains a long-term overhang.

Padcev, the targeted bladder cancer therapy developed with Astellas, posted USD 591 million in sales, up 39% operationally. Market share gains in first-line locally advanced and metastatic urothelial cancer, combined with expanding indications, are driving sustained momentum. A supplemental biologics application for perioperative use regardless of cisplatin eligibility is currently under FDA priority review, with a PDUFA date of August 17, 2026.

Nurtec ODT, the migraine therapy, rose 41% operationally, benefiting from strong U.S. demand and one-time net price favourability. Lorbrena, used in ALK-positive non-small cell lung cancer, grew 32% operationally, supported by share gains in the U.S., China, and select international markets. Abrysvo, Pfizer's RSV vaccine, contributed USD 180 million, up 37% from the year-ago period. Oncology biosimilars expanded 52% operationally, partly reflecting one-time pricing and supply recovery benefits.

Covid Revenue: Structural, Not Cyclical

The continued deterioration of Covid-related revenue is no longer a surprise, but the scale of quarterly decline warrants attention. Paxlovid generated USD 186 million in Q1 2026, down 63% operationally, as infection rates declined across major markets and government procurement activity fell. Comirnaty contributed USD 232 million, down 59% operationally, reflecting narrower vaccination recommendations in the U.S. and reduced international contractual deliveries.

Pfizer's own guidance anticipates Covid product revenues falling approximately USD 1.5 billion year over year to around USD 5 billion for full-year 2026. Separately, the loss of market exclusivity across certain products is expected to cost another USD 1.5 billion in annual revenue. The company's ability to grow revenue in this environment depends almost entirely on execution in its launched and acquired portfolio, a test the first quarter passed, though not by a wide margin at the operational level.

Pipeline and Capital Allocation

Pfizer invested USD 2.5 billion in internal R&D during the quarter, with R&D expenses rising 12% operationally as oncology and obesity programmes advanced. The company's USD 10 billion acquisition of Metsera, an obesity-focused biotech, signals a strategic pivot toward the GLP-1 and metabolic therapy space, a market with significant long-term addressable opportunity. The company expects approximately 20 pivotal study starts in 2026.

Positive Phase 3 readouts for Elrexfio in multiple myeloma and expanded regulatory approvals for Braftovi in metastatic colorectal cancer add further credibility to the oncology pipeline narrative. The Vyndaqel family, which treats transthyretin amyloid cardiomyopathy, grew 4% operationally globally, supported by Pfizer extending U.S. patent protection for Vyndamax to June 2031 through settlements with three generic manufacturers.

Capital returns remain anchored to dividends, with USD 2.4 billion, or USD 0.43 per share, returned to shareholders in the quarter. No share repurchases were completed, and the current guidance does not anticipate any buybacks for 2026 as the company prioritises balance sheet de-leveraging.

Guidance Holds, But Execution Risk Remains

Management reaffirmed full-year 2026 guidance of USD 59.5 to USD 62.5 billion in revenue and USD 2.80 to USD 3.00 in adjusted EPS. That revenue range implies roughly flat to modestly declining top-line performance compared to 2025's USD 62.6 billion. The guidance is not ambitious, but it is credible given the known headwinds. Adjusted SI&A expenses are guided between USD 12.5 and USD 13.5 billion, and adjusted R&D between USD 10.5 and USD 11.5 billion. An effective tax rate of approximately 15% on adjusted income is expected.

The strategic thesis is clear: absorb the Covid revenue decline, grow the non-Covid portfolio aggressively, and build a meaningful presence in oncology and obesity over the medium term. Whether the pipeline can scale quickly enough to offset structural revenue pressures before investor patience thins remains the central valuation question for Pfizer in 2026.

Conclusion

Pfizer's Q1 2026 results confirm that the underlying commercial portfolio is functioning. Revenue beat expectations, new and acquired products are gaining traction, and guidance was not cut. However, the adjusted EPS decline from USD 0.92 to USD 0.75 year over year illustrates that profitability remains compressed even in a quarter where sales surprised positively. With Covid revenues continuing to diminish and patent expirations adding further pressure, the pace of pipeline conversion, particularly in oncology and obesity, will define whether Pfizer's current valuation reflects fair value or deferred risk. The first quarter provides a foundation; it does not resolve the longer-term question.